Protalix Biotherapeutics, Inc. (PLX)
1.79
-0.04
(-2.19%)
USD |
NYAM |
Dec 12, 16:00
1.795
0.00 (0.00%)
After-Hours: 20:00
Protalix Biotherapeutics Research and Development Expense (Quarterly): 4.467M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Agenus, Inc. | 23.60M |
| Curis, Inc. | 6.432M |
| Halozyme Therapeutics, Inc. | 17.25M |
| AIM ImmunoTech, Inc. | 0.525M |
| Armata Pharmaceuticals, Inc. | 5.824M |